JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,” “we,” “us,” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on improving, applying and deploying its proprietary C1 cell protein production platform to accelerate development, reduce production costs, while improving commercial scales to improve access to animal health biologics and human, today announced its industrially proven C1-cells have been designed to demonstrate the potential for manufacturing therapeutically viable and commercially useful cannabis compounds, including cannabidiol (CBD) and its precursors using synthetic biology. C1 cells have the potential to be an easy way to produce pure synthetic cannabinoids for commercial use that is cheaper and more efficient than conventional extraction methods using hemp and the marijuana plant, Cannabis sativa.

“For the consumer, the potential benefits are high-quality, low-cost CBD, other forms of cannabinoids, and THC. You can get exactly what you want from C1 cells,” said Dr. Ronen Tchelet, Director Dyadic scientist Dr. Tchelet continued: “Fungal filamentous cell factories should be more environmentally friendly and less energy intensive than growing the plant and separating the psychoactive and non-psychoactive ingredients. They can also produce derivatives of cannabinoids with unexpected medical uses Interest in CBD and other forms of cannabinoids has grown as previous studies have demonstrated the bioactive effects of CBD in animals and humans through numerous receptor pathways of CBD.In particular, in the immune system which has demonstrated mediating therapeutic effects related to inflammation in animal models. binoids and preparations of cannabis material have recently found application as therapeutics for chronic pain, multiple sclerosis, cancer-associated nausea and vomiting, weight loss, loss of appetite, spasticity and d other conditions. It has recently been reported that two cannabinoid acids, CBGA and CBDA, which are commonly found in hemp-based cannabis strains, can bind to the coronavirus spike protein, which may help prevent infection. infection of human cells. The study also reported that cannabigerolic acid and cannabidiolic acid were equally effective against SARS-CoV-2 alpha variant B.1.1.7 and beta variant B.1.351. The study from which these results were derived was conducted in collaboration with scientists from Oregon Health & Science University and recently published by the ‘ Natural Products Journal.’”

While synthetic cannabinoid compounds have been approved by the FDA, chemical synthesis is relatively expensive and may involve the use of chemicals that are not environmentally friendly, and, more importantly, various chemically synthesized cannabinoids have been classified as less pharmacologically active than those extracted. from plants such as the sativa strain of cannabis.

Dyadic’s synthetic biology C1 cannabinoid production process has the potential to develop commercially viable biological methods of producing CBD, such as cannabigerolic acid (CBGA), cannabigerovarinic acid (CBGVA), tetrahydrocannabinolic acid ( THCA), cannabidiolic acid (CBDA) and cannabidivarinic acid (CBVA) and their uses for producing said precursors and cannabinoids.

“We are excited to present a new synthetic production method to produce CBD and precursor molecules from filamentous fungi. As with other commercially proven applications that have been enhanced using Dyadic’s C1 production platform, there are distinct potential advantages over the natural extraction of CBD and other cannabinoids from plants. We believe that the company’s C1 production platform can be used to produce a purer, regulatory-compliant end product that is not only economical, but more environmentally friendly compared to conventional cannabinoid production processes. plant derivatives. We also believe that by using synthetic biology to engineer and further optimize the production of C1 cells to produce CBD, other cannabinoids and THC will attract great interest in light of the burgeoning potential uses of CBD and THC. ‘other cannabinoids in animal and human health, including medical and recreational marijuana and cannabinoid products, such as CBD,’ said Mr. Emalfarb, CEO of Dyadic.

“Our decision to engineer C1 cells for the production of CBD and other cannabinoids is part of the company’s synthetic biology programs, and as part of Dyadic’s 2022 strategic operating plan, we are focusing on three business areas majors: (i) human health with a focus on infectious diseases, including COVID-19, (ii) non-infectious diseases in human and animal health, and (iii) other biologicals, including enzymes and metabolites,” said Joe Hazelton, Chief Commercial Officer of Dyadic. “Furthermore, as we look to the year ahead, Dyadic intends to further advance and grow our portfolio of assets, both internally and through joint ventures, licensing, partnerships and other collaborations,” concluded Mr. Hazelton.

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company developing what it believes to be a potentially important biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the large-scale development and manufacture of proteins at low cost, has the potential to be further developed into a safe and efficient expression system that can help accelerate development, reduce production costs and to improve the performance of biology. vaccines and drugs at flexible commercial scales. Dyadic uses C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus particles (VLPs) and antigens, antibodies monoclonals, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Some other research activities are ongoing, including exploring the use of C1 to develop and produce certain metabolites and other biologics. Dyadic pursues research and development collaborations, licensing agreements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in the development and manufacturing of biopharmaceuticals. As the aging population grows in both developed and underdeveloped countries, Dyadic believes C1 technology can help bring biologic vaccines, drugs, and other biologics to market faster, in greater volumes, at lower cost, and with new properties for drug developers and manufacturers, and improving access and cost for patients and the healthcare system, but above all saving lives.

Please visit the Dyadic website at http://www.dyadic.com for more information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding Dyadic’s expectations, intentions, strategies and beliefs regarding future events or financial performance. Forward-looking statements can generally be identified by the use of the words “expect”, “should”, “intend”, “aim”, “anticipate”, “believe”, “will”, “project ‘, ‘may’, ‘could’, ‘potential’, ‘pursue’ or ‘continue’ and other similar terms or variations thereof or similar terminology. However, not all forward-looking statements contain these words. Actual events or results may differ materially from those contained in the forward-looking statements due to a variety of important factors, including (1) general economic, political and market conditions; (2) our ability to generate the productivity, stability, purity, performance, cost, safety and other data necessary to complete and implement our biopharmaceutical research, business plans and strategic initiatives ; (3) our ability to implement and complete the research and development efforts of Dyadic and third parties; (4) the willingness of the pharmaceutical and biotechnology industry, government regulators and other organizations to adopt, use and approve the use of the C1 gene expression platform; and (5) other factors described in the Company’s latest filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this press release speak only as of the date hereof, and Dyadic does not intend, and except as required by law, assumes no obligation to publicly update such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section titled “Risk Factors” in Dyadic’s Annual Reports on Form 10-K and Quarterly Reports on Form 10. -Q filed with the Securities and Exchange Commission (the “SEC”), as these factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and www.dyadic.com.

contacts:

Dyadic International, Inc. Ping W. Rawson Chief Financial Officer Phone: (561) 743-8333 Email: [email protected]

Previous

'LeBron James becomes the first player in NBA history to record 30,000 points, 10,000 rebounds and 9,000 assists': The 37-year-old was the only saving grace in the Lakers' embarrassing loss to the Pacers

Next

Intevac Appoints Nigel Hunton as Chief Executive Officer - Form 8-K

Check Also